+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

From the Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin



From the Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin



JAMA 278(6): 461-462




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046128750

Download citation: RISBibTeXText

PMID: 9256209


Related references

Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. Mmwr. Morbidity and Mortality Weekly Report 46(27): 626-8, 635, 1997

From the Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. JAMA 283(5): 597-598, 2000

Centers For Disease Control And Prevention Issues Interim Guidelines For Pregnant Women And Infants Exposed To Zika Virus And Prevention Of Sexually Transmitted Zika Infection. Journal of Midwifery & Women's Health 61(3): 392-394, 2016

From the Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. JAMA 278(11): 891-892, 1997

From the Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. JAMA 278(14): 1145-1146, 1997

From the Centers for Disease Control and Prevention. Guidelines for surveillance, prevention, and control of West Nile virus infection--United States. JAMA 283(8): 997-998, 2000

Improved compliance with the centers for disease control and prevention guidelines for vancomycin use. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 303, 1997

From the Centers for Disease Control and Prevention. Interim guidelines for investigation of and response to Bacillus anthracis exposures. JAMA 286(20): 2540-2541, 2002

From the Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. JAMA 281(9): 787-789, 1999

Laboratory management of agents associated with hantavirus pulmonary syndrome: interim biosafety guidelines. Centers for Disease Control and Prevention. Mmwr. Recommendations and Reports 43(Rr-7): 1-7, 1994

Knowledge of Centers for Disease Control and Prevention guidelines for the use of vancomycin at a large tertiary care children's hospital. Journal of Pediatrics 137(5): 694-700, 2000

Evaluation of infection control parameters according to the 1994 centers for disease control and prevention tuberculosis guidelines: A 2-year experience. American Journal of Infection Control 26(3): 224-231, 1998

Tuberculosis epidemiology, diagnosis and infection control recommendations for dental settings: an update on the Centers for Disease Control and Prevention guidelines. Journal of the American Dental Association 140(9): 1092-1099, 2009

Advancing infection control in dental care settings: factors associated with dentists' implementation of guidelines from the Centers for Disease Control and Prevention. Journal of the American Dental Association 143(10): 1127-1138, 2013

From the Centers for Disease Control and Prevention. Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. JAMA 286(17): 2086-2088, 2002